Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
LAS VEGAS, Jan. 03, 2018 -- CV Sciences, Inc., (OTCQB:CVSI) (the "Company," "CV Sciences," "our" or "we"), preeminent supplier and manufacturer of hemp-derived phytocannabinoids, including CBD oil and developer of specialty pharmaceutical therapeutics, announced today that it will be presenting at the Biotech Showcase™ 2018. The conference will be held January 8-10, 2018 at the Hilton San Francisco Union Square in San Francisco, California. Joseph Dowling, Chief Financial Officer of CV Sciences, Inc., will deliver the Company’s presentation and conduct meetings with investors.
Mr. Dowling’s presentation will highlight CV Sciences' line of CBD consumer products as well as discuss its lead drug candidate, CVSI-007, which utilizes synthetically-formulated CBD for use in the treatment of smokeless tobacco addiction.
Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
CONTACT INFORMATION:
Robert Haag
Managing Director
IRTH Communications
[email protected]
866-976-4784
